IL123848A - Tobramycin aerosol formulation for treatment and prevention of pulmonary diseases caused by mycobacterium tuberculosis and/or mycobacterium bovis - Google Patents

Tobramycin aerosol formulation for treatment and prevention of pulmonary diseases caused by mycobacterium tuberculosis and/or mycobacterium bovis

Info

Publication number
IL123848A
IL123848A IL12384898A IL12384898A IL123848A IL 123848 A IL123848 A IL 123848A IL 12384898 A IL12384898 A IL 12384898A IL 12384898 A IL12384898 A IL 12384898A IL 123848 A IL123848 A IL 123848A
Authority
IL
Israel
Prior art keywords
tobramycin
formulation
tuberculosis
aerosol
nebulizer
Prior art date
Application number
IL12384898A
Other languages
English (en)
Other versions
IL123848A0 (en
Original Assignee
Pathogenesis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pathogenesis Inc filed Critical Pathogenesis Inc
Publication of IL123848A0 publication Critical patent/IL123848A0/xx
Publication of IL123848A publication Critical patent/IL123848A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL12384898A 1997-04-02 1998-03-26 Tobramycin aerosol formulation for treatment and prevention of pulmonary diseases caused by mycobacterium tuberculosis and/or mycobacterium bovis IL123848A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/825,725 US6083922A (en) 1996-04-02 1997-04-02 Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis

Publications (2)

Publication Number Publication Date
IL123848A0 IL123848A0 (en) 1998-10-30
IL123848A true IL123848A (en) 2002-12-01

Family

ID=25244769

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12384898A IL123848A (en) 1997-04-02 1998-03-26 Tobramycin aerosol formulation for treatment and prevention of pulmonary diseases caused by mycobacterium tuberculosis and/or mycobacterium bovis

Country Status (7)

Country Link
US (1) US6083922A (es)
AR (1) AR011706A1 (es)
AU (1) AU6469198A (es)
BR (1) BR9801008A (es)
IL (1) IL123848A (es)
WO (1) WO1998043650A1 (es)
ZA (1) ZA982447B (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW465235B (en) 1998-09-17 2001-11-21 United Video Properties Inc Electronic program guide with digital storage
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
AU2002247280A1 (en) * 2001-03-09 2002-09-24 Antares Pharma, Inc. Ocular drug delivery nebulizer
AU2007202942B2 (en) * 2001-05-18 2010-05-27 Novartis Ag Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
EP1598059A1 (en) * 2001-05-18 2005-11-23 Chiron Corporation Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
CA2447600C (en) * 2001-05-18 2015-10-20 Chiron Corporation Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
WO2003037365A1 (en) * 2001-11-01 2003-05-08 The Johns Hopkins University Methods and compositions for treating vascular leak using hepatocyte growth factor
US20050220720A1 (en) * 2002-05-02 2005-10-06 David Edwards Formulations limiting spread of pulmonary infections
WO2003092654A1 (en) 2002-05-02 2003-11-13 President And Fellows Of Harvard College Formulations limiting spread of pulmonary infections
US7607436B2 (en) * 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
US8245708B2 (en) * 2002-05-07 2012-08-21 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
US8012136B2 (en) 2003-05-20 2011-09-06 Optimyst Systems, Inc. Ophthalmic fluid delivery device and method of operation
EP1624938B1 (en) 2003-05-20 2011-03-16 James F. Collins Ophthalmic drug delivery system
US20070071686A1 (en) * 2003-10-15 2007-03-29 Pari Gmbh Liquid preparation containing tobramycin
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
ES2392389T3 (es) * 2004-05-17 2012-12-10 Gilead Sciences, Inc. Combinación de fosfomicina/aminoglucósido aerosolizada para el tratamiento de las infecciones respiratorias bacterianas
US8627821B2 (en) * 2005-01-10 2014-01-14 Pulmatrix, Inc. Method and device for decreasing contamination
CN101247898B (zh) * 2005-05-05 2011-01-26 普马特里克斯公司 超音波气雾产生器
EP2308469A1 (en) * 2005-05-18 2011-04-13 Pulmatrix, Inc. Formulations for alteration of biophysical properties of mucosal lining
US8524734B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
PT2594272T (pt) 2005-05-18 2018-07-31 Horizon Orphan Llc Fluoroquinolonas aerossolizadas e suas utilizações
CA2622193A1 (en) * 2005-09-29 2007-04-12 Nektar Therapeutics Antibiotic formulations, unit doses, kits, and methods
EP2012801A4 (en) 2006-04-24 2009-08-05 Gloucester Pharmaceuticals Inc GEMCITABINE COMBINATION THERAPY
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
EP2061772A4 (en) 2006-09-11 2011-06-29 Curis Inc MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES
JP2008199905A (ja) * 2007-02-16 2008-09-04 Snow Brand Milk Prod Co Ltd 乳酸菌生残性向上剤
HUE038428T2 (hu) 2008-10-07 2018-10-29 Horizon Orphan Llc Aeroszol fluorokinolon készítmények javított farmakokinetika érdekében
SI2346509T1 (sl) 2008-10-07 2020-08-31 Horizon Orphan Llc Inhalacija levofloksacina za zmanjšanje vnetja pljuč
KR101411889B1 (ko) 2009-02-27 2014-06-27 이난타 파마슈티칼스, 인코포레이티드 Ｃ형 간염 바이러스 억제제
RS56352B2 (sr) 2009-06-25 2023-02-28 Alkermes Pharma Ireland Ltd Heterociklična jedinjenja za lečenje neuroloških i psiholoških poremećaja
US20110014273A1 (en) * 2009-07-15 2011-01-20 Helmut Brunar Method of Treating BCC
BR112012004692B8 (pt) 2009-09-04 2021-05-25 Mpex Pharmaceuticals Inc solução que compreende levofloxacina para uso em um método para tratar a fibrose cística em um ser humano
EP2521711B1 (en) 2010-01-07 2017-08-16 Alkermes Pharma Ireland Limited Quaternary ammonium salt prodrugs
ES2691671T3 (es) 2010-06-24 2018-11-28 Alkermes Pharma Ireland Limited Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
KR20170129298A (ko) 2010-07-15 2017-11-24 아이노비아 인코포레이티드 안과용 약물 전달
WO2012009702A1 (en) 2010-07-15 2012-01-19 Corinthian Ophthalmic, Inc. Method and system for performing remote treatment and monitoring
CN103118642B (zh) 2010-07-15 2015-09-09 艾诺维亚股份有限公司 液滴生成装置
EP2464346A1 (en) 2010-08-30 2012-06-20 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
JP5877201B2 (ja) 2010-08-30 2016-03-02 パルマトリックス，インコーポレイテッド 肺疾患を治療するための乾燥粉末製剤および方法
DK2621488T3 (en) 2010-09-29 2019-03-04 Pulmatrix Operating Co Inc CATIONIC DRY POWDER
CN103228273B (zh) 2010-09-29 2017-04-05 普马特里克斯营业公司 吸入用单价金属阳离子干粉剂
AU2011348085B2 (en) 2010-12-23 2016-12-08 Alkermes Pharma Ireland Limited Multi- API loading prodrugs
TWI574687B (zh) 2011-01-03 2017-03-21 古利斯股份有限公司 具有鋅結合部份之刺蝟拮抗劑
US10092552B2 (en) 2011-01-31 2018-10-09 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
PL2694075T3 (pl) 2011-04-01 2016-09-30 Inhibitor 3-kinazy fosfoinozytydowej z grupą wiążącą cynk
WO2013090459A1 (en) 2011-12-12 2013-06-20 Corinthian Ophthalmic, Inc. Ejector mechanism, ejector device, and methods of use
JP5952912B2 (ja) 2011-12-15 2016-07-13 アルカーメス ファーマ アイルランド リミテッド 二級アミン化合物のプロドラッグ
HUE044957T2 (hu) 2011-12-15 2019-11-28 Alkermes Pharma Ireland Ltd Samidorphan (ALKS 33) opioid agonistákkal alkotott kombinációja
CA2865972C (en) 2012-02-29 2022-01-04 Pulmatrix, Inc. Inhalable dry powders
EP2877164B1 (en) 2012-07-24 2023-07-05 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds
WO2014160478A1 (en) 2013-03-13 2014-10-02 Flatley Discovery Lab Compounds and methods for the treatment of cystic fibrosis
CA2907566C (en) 2013-04-01 2023-08-22 Pulmatrix, Inc. Tiotropium dry powders
WO2015017728A1 (en) 2013-07-31 2015-02-05 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
SG10201808565QA (en) 2014-03-31 2018-11-29 Debiopharm Int Sa Fgfr fusions
CN106794243A (zh) 2014-08-26 2017-05-31 哈斯福制药公司 新型免疫剂及其使用方法
MX2017004471A (es) 2014-10-06 2017-11-20 Flatley Discovery Lab Llc Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
EP3426245B1 (en) 2016-03-07 2022-12-14 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
EP3512602B1 (en) 2016-09-16 2024-03-27 HSF Pharmaceuticals Inhibitors of heat shock factors (hsf) and uses thereof
US11938056B2 (en) 2017-06-10 2024-03-26 Eyenovia, Inc. Methods and devices for handling a fluid and delivering the fluid to the eye
WO2019110099A1 (en) 2017-12-06 2019-06-13 Qrumpharma Inc. Inhalable clofazimine formulation
WO2019170871A1 (en) 2018-03-08 2019-09-12 Hsf Pharmaceuticals Localized activation of virus replication boosts herpesvirus-vectored vaccines
US20210128735A1 (en) 2018-05-10 2021-05-06 Cis Pharma Ag Biocompatible copolymer containing multiple active agent molecules
CN112804993A (zh) 2018-08-23 2021-05-14 曼金德公司 氯法齐明的组合物，含它们的组合，它们的制备方法，含它们的用途和方法
JP2022500466A (ja) 2018-09-21 2022-01-04 エナンタ ファーマシューティカルズ インコーポレイテッド 抗ウイルス剤としての官能化複素環
EP3653716A1 (en) 2018-11-19 2020-05-20 HSF Pharmaceuticals Replication-competent controlled alpha-herpesvirus virus vectors and uses therefore
CA3142109A1 (en) 2019-06-04 2020-12-10 Thirty Respiratory Limited Methods and compositions for generating nitric oxide and uses thereof to deliver nitric oxide via the respiratory tract
EP3980373A1 (en) 2019-06-04 2022-04-13 Thirty Holdings Limited Methods and compositions for generating nitric oxide and uses thereof
CA3150503A1 (en) 2019-10-30 2021-05-06 Cis Pharma Ag BIOCOMPATIBLE POLYMERIC MEDICATION CARRIES FOR THE DELIVERY OF ACTIVE AGENTS
WO2021214439A1 (en) 2020-04-23 2021-10-28 Thirty Respiratory Limited Methods and compositions for treating and combatting tuberculosis
GB2610722A (en) 2020-04-23 2023-03-15 Thirty Respiratory Ltd Nitric oxide or nitric oxide releasing compositions for use in treating SARS-COV and SARS-COV-2
EP4138898A1 (en) 2020-04-24 2023-03-01 HSF Pharmaceuticals Replication-competent controlled herpesviruses expressing a sars cov-2 antigen
EP4157237A2 (en) 2020-06-01 2023-04-05 Advent Therapeutics Inc. Pharmaceutical compositions comprising insoluble active ingredients
EP4167984A1 (en) 2020-06-23 2023-04-26 Flagship Pioneering, Inc. Anti-viral compounds and methods of using same
CN116348477A (zh) 2020-07-20 2023-06-27 英安塔制药有限公司 作为抗病毒剂的功能化肽
UY39529A (es) 2020-11-23 2022-06-30 Enanta Pharm Inc Nuevos agentes antivirales derivados de espiropirrolidina
WO2022240897A1 (en) 2021-05-10 2022-11-17 Sepelo Therapeutics, Llc Pharmaceutical composition comprising delafloxacin for administration into the lung
WO2023006993A1 (en) 2021-07-30 2023-02-02 Atmosr Fused amino pyridine or pyrimidine derivatives for the treatment of congenital central hypoventilation syndrome
WO2023028364A1 (en) 2021-08-27 2023-03-02 Sepelo Therapeutics, Llc Targeted compositions and uses therof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US5284133A (en) * 1992-07-23 1994-02-08 Armstrong Pharmaceuticals, Inc. Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization

Also Published As

Publication number Publication date
US6083922A (en) 2000-07-04
AU6469198A (en) 1998-10-22
BR9801008A (pt) 2001-03-20
ZA982447B (en) 1999-01-26
WO1998043650A1 (en) 1998-10-08
AR011706A1 (es) 2000-08-30
IL123848A0 (en) 1998-10-30

Similar Documents

Publication Publication Date Title
US6083922A (en) Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5508269A (en) Aminoglycoside formulation for aerosolization
US6387886B1 (en) Method for the treatment of severe chronic bronchitis (bronchietasis) with an aerosolized antibiotic
JP4646489B2 (ja) 肺細菌感染症の治療及び予防のための吸入可能なアズトレオナム
US9345663B2 (en) Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
AU2002231244A1 (en) Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections
BG66328B1 (bg) Аерозолен състав на тобpамицин
US20230201309A1 (en) Compositions for the treatment of a respiratory condition
AU2004257632C1 (en) Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
Le Le et al. Consensus Summary of Aerosolized Antimicrobial Agents: Application of Guideline Criteria: Insights from the Society of Infectious Diseases Pharmacists
MXPA01006134A (es) Metodo para el tratamiento de bronquitis cronica severa (bronquiectasis) con un antibiotico en forma de aerosol

Legal Events

Date Code Title Description
FF Patent granted
FF Patent granted
KB20 Patent renewed for 20 years
EXP Patent expired